Until that day, companies in the healthcare sector that can stay ahead of the curve will continue to thrive. Although this market is competitive, the company made its name by targeting the life sciences industry. In other words, Veeva Systems is a specialist, not a generalist.
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
COPENHAGEN (Reuters) -Danish drug maker Novo Nordisk said on Tuesday it plans to invest 5.4 billion Danish crowns ($744 million) to expand its facilities in Bagsvaerd, Denmark. The world's biggest producer of diabetes drugs, Novo said the project is expected to be finalised in 2024 and create about 160 new jobs. The investment would add capacity in research and development for manufacturing of active pharmaceutical ingredients (API), the main biologically active components of medicines, to supply its global clinical trials.